The FDA granted Fast Track designation to elunetirom, an oral CNS thyroid hormone receptor agonist, for adjunctive treatment of bipolar depression, while the agent remains in a 30-participant open-label phase 2 trial with no human efficacy data yet available.

Baseline cognitive performance predicted future depression risk in opposite directions depending on depression history: lower cognition signaled higher risk in never-depressed controls, while higher cognition was associated with greater relapse risk in remitted depression, in a longitudinal UK Biobank analysis of 3,724 participants.

A middle-aged woman with a four-year bipolar disorder diagnosis continued deteriorating despite psychiatric treatment until clinical reassessment pointed toward anti-NMDA receptor encephalitis, an autoimmune condition whose psychiatric prodrome frequently delays correct diagnosis.

A single 25-mg dose of synthetic psilocybin with structured psychological support produced rapid, large-magnitude reductions in suicidal ideation through 12 weeks in 20 treatment-resistant adults with major depressive disorder, with two participants experiencing worsening ideation.

Antidepressant prescription trajectories remained stable or absent for the majority of Swedish adults who continued working past age 65, with no worsening pattern observed around work exit in a 10-year longitudinal cohort of 32,849 participants.

Perioperative apalutamide plus ADT, six months before and after radical prostatectomy, achieved a ninefold improvement in major pathologic response and a 20% reduction in metastasis-free survival events versus placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer in a phase 3 trial.